Overview

Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer

Status:
Completed
Trial end date:
2002-02-10
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of topotecan plus sargramostim in treating patients who have advanced cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Yale University
Collaborator:
National Cancer Institute (NCI)
Treatments:
Sargramostim
Topotecan